Current Problems in Pediatric and Adolescent Health Care
Volume 39, Issue 4 , Pages 97-140 , April 2009

Mosquito-borne Diseases

References 

  1. Reiter P. Climate change and mosquito-borne disease. Environ Health Perspect. 2001;109(S1):141–161
  2. White NJ. Malaria. In:  Cook GC,  Zumla AI editor. Manson's Tropical Diseases. 21st Edition. London, England: Elsevier; 2004;
  3. Milner DA, Montgomery J, Seydel KB, Rogerson SJ. Severe malaria in children and pregnancy: an update and perspective. Trends Parasitol. 2008;24(12):590–595
  4. World Health Organization. Malaria Treatment Guidelines. Accessed January 9, 2009 http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
  5. U.S. Centers for Disease Control and Prevention. Yellow fever. In:  Arguin PM,  Kozarsky PE,  Reed C editor. Health information for international travel, 2008. Atlanta: Centers for Disease Control and Prevention; 2007;
  6. World Health Organization. Dengue, dengue hemorrhagic fever and dengue shock syndrome in the context of the integrated management of childhood illness. Accessed January 9, 2009 http://whqlibdoc.who.int/hq/2005/WHO_FCH_CAH_05.13_eng.pdf2005;
  7. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis (West Nile and dengue viruses). Nat Med. 2004;10(12):S98–S109
  8. World Health Organization. Management of Severe Malaria: a practical handbook. Accessed January 9, 2009 http://www.searo.who.int/LinkFiles/Malaria_Mgmtseveremalaria2.pdf2000;
  9. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS Bellagio Child Survival Study Group. How many child deaths can we prevent this year?. Lancet. 2003;362:65–71
  10. Fegan GW, Noor AM, Akhwale WS, Cousens S, Snow RW. Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet. 2007;370:1035–1039
  11. Is malaria eradication possible?. Lancet. 2007;370:1459
  12. Halstead SB. Dengue. Lancet. 2007;370:1644–1652
  13. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2:519–529
  14. Pialoux G, Gauzere B, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirus. Lancet Infect Dis. 2007;7:319–327
  15. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet. 2008;371:500–509
  16. Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med. 2007;14(4):259–268
  17. The Global Alliance to Eliminate Lymphatic Filariasis website. Accessed January 9, 2009 www.filariasis.org
  18. White GB. Medical acarology and entomology: mosquitoes. In:  Cook GC,  Zumla AI editor. Manson's Tropical Diseases. 21st Edition. London, England: Elsevier; 2004;
  19. Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Am J Trop Med Hyg. 1989;40(6):571–578
  20. Afrane YA, Little TJ, Lawson BW, Githeko AK, Yan G. Deforestation and vectorial capacity of Anopheles gambiae giles mosquitoes in malaria transmission. Emerg Infect Dis. 2008;14(10):1533–1538
  21. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352:1565–1577
  22. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life-threatening. Clin Infect Dis. 2008;46:165–171
  23. Alsop Z. Malaria returns to Kenya's highlands as temperatures rise. Lancet. 2007;370:925–926
  24. Stauffer W, Fischer PR. Diagnosis and treatment of malaria in children. Clin Infect Dis. 2003;37:1340–1348
  25. World Health Organization. A strategic framework for malaria prevention and control during pregnancy in the Africa region. World Health Organization Regional Office for Africa; 2004;Accessed January 9, 2009 at: http://www.afro.who.int/malaria/publications/malaria_in_pregnancy_092004.pdf.
  26. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813–822
  27. Hamer DH, Mwanakasale V, MacLeod WB, Chalwe V, Mukwamataba D, Champo D, et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis. 2007;196:1585–1594
  28. Vallely A, Vallely L, Changalucha J, Greenwood B, Chandramohan D. Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed?. Malaria J. 2007;6:16–28
  29. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA. 2006;296(18):2234–2244
  30. Fischer PR, Bialek R. Prevention of malaria in children. Travel Med. 2002;34:493–498
  31. Freedman DO. Malaria prevention in short-term travelers. N Engl J Med. 2008;359:603–612
  32. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States—a systematic review. JAMA. 2007;297(20):2264–2277
  33. Tijtra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua Indonesia. PLoS Med. 2008;5:e128
  34. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study in Papua New Guinea. PLoS Med. 2008;5:e127
  35. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg. 2006;75(5):790–797
  36. Beare NA, Southern C, Chalira C, Taylor TE, Molyneux ME, Harding SP. Prognostic significance and course of retinopathy in children with severe malaria. Arch Ophthalmol. 2004;122:1141–1147
  37. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis. 2005;191:1932–1939
  38. Font F, Alonso Gonzalez M, Nathan R, Kimario J, Lwilla F, Ascaso C, et al. Diagnostic accuracy and case management of clinical malaria in the primary health services of a rural area in south-eastern Tanzania. Trop Med Int Health. 2001;6:423–428
  39. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004;329:1212
  40. McMorrow ML, Masanja MI, Abdulla SM, Kahigwa E, Kachur SP. Challenges in routine implementation and quality control of rapid diagnostic tests for malaria—Rufiji District, Tanzania. Am J Trop Med Hyg. 2008;79(3):385–390
  41. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al. UK malaria treatment guidelines. J Infect. 2007;54:111–121
  42. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15:66–78
  43. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, et al. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomized trial. BMJ. 2007;334:403–409
  44. Harvey SA, Jennings L, Chinyama M, Masaninga F, Mulholland K, Bell DR. Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid job aid-plus-training. Malaria J. 2008;7:160–171
  45. Mens P, Spieker N, Omar S, Heijnen M, Schallig H, Kager PA. Is molecular biology the best alternative for diagnosis of malaria to microscopy? (A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania). Trop Med Int Health. 2007;12(2):238–243
  46. Mayxay M, Pukritayakamee S, Chotivaninch K, Looareesuwan S, White NJ. Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg. 2001;95:179–182
  47. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med. 2008;358:1829–1836
  48. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for the treatment of severe falciparum malaria: a randomized trial. Lancet. 2005;366:717–725
  49. Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2007;4:CD005967
  50. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98:261–269
  51. World Health Organization. Malaria vector control and personal protection. Accessed January 9, 2009 http://www.who.int/malaria/docs/WHO-TRS-936s.pdf2006;
  52. World Health Organization. Indoor residual spraying: Use of indoor residual spraying for scaling up global malaria control and elimination. Accessed January 9, 2009 http://www.who.int/malaria/docs/IRS/IRS-position.pdf2006;
  53. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev. 2004;2:CD000363
  54. Noor AM, Amin AA, Akhwale WS, Snow RW. Increasing covereage and decreasing inequity in insecticide-treated bed net use among rural Kenyan children. PLoS Med. 2007;4:1341–1348
  55. Minakawa N, Dida GO, Sonye GO, Futami K, Kaneko S. Unforeseen misuses of bed nets in fishing villages along Lake Victoria. Malaria J. 2008;7:165–170
  56. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomized controlled trials. PLoS Med. 2007;4(3):0506–0515
  57. Schhwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandi ST, Newman RD, et al. Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis. 2008;47:1017–1025
  58. Ayisi JG, van Ejik AM, ter-Kuile FO, Kolczak MS, Otieno JA, Misore AO, et al. The effect of dual infection with HIV and malaria on pregnancy outcomes in western Kenya. AIDS. 2003;17:585–594
  59. Brahmbhatt H, Sullivan D, Kigozi G, Askin F, Wabwire-Mangenm F, Serwadda D, et al. Association of HIV and Malaria with mother-to-child transmission, birth outcomes, and child mortality. J Acquir Immune Defic Syndr Hum Retrovirol. 2008;47:472–476
  60. d'Alessandro UD, ter Kuile FO. Amodiaquine, malaria, pregnancy: the old new drug. Lancet. 2006;368:1306–1307
  61. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994;51:515–522
  62. Cisse B, Sokhna C, Boulanger D, Milet J, Ba E, Richardson K, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Lancet. 2006;367:659–667
  63. Gimnig JE, MacArthur JR, M'bang'ombe M, Kramer MH, Chizani M, Stern RS, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg. 2006;74:738–743
  64. Geerligs PD, Brabin BJ, Eggelete TA. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ. 2003;81:205–216
  65. Sokhna C, Cisse B, Ba EH, Milligan P, Hallett R, Sutherland C, et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One. 2008;1:1–9
  66. Ntab B, Cisse B, Boulanger D, Sokhna C, Targett G, Lines J, et al. Impact of intermittent preventive anti-malarial treatment on the growth and nutritional status of preschool children in rural Senegal (West Africa). Am J Trop Med Hyg. 2007;77(3):411–417
  67. Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, Otido J, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:127–138
  68. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. Intermittent preventive antimalarial treatment for Tanzanian infants; follow-up to age 2 years of a randomized, placebo-controlled trial. Lancet. 2005;365:1481–1483
  69. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants. Assessment of the role of intermittent preventive treatment for malaria in infants: letter report. National Academies Press; 2008;Accessed January 9, 2009 at http://www.nap.edu/catalog.php?record_id=12180.
  70. Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med. 2006;75(Suppl 2):111–118
  71. Vanderberg JP. Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine. 2009;27(1):2–9
  72. Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007;25:1567–1580
  73. Tetteh K, Polley SD. Progress and challenges towards the development of malaria vaccines. Biodrugs. 2007;21(6):357–373
  74. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02A malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial. Lancet. 2001;358:1927–1934
  75. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of RTS,S/AS02A malaria vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet. 2004;364:1411–1420
  76. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized-controlled trial. Lancet. 2005;366:2012–2018
  77. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet. 2007;370:1543–1551
  78. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185(6):820–827
  79. Epstein JE. What will a partially protective malaria vaccine mean to mothers in Africa?. Lancet. 2007;370:1523–1524
  80. Rafikov M, Bevilacqua L, Wyse APP. Optimal control strategy of malaria vector using genetically modified mosquitoes. J Theor Biol. 2008;doi:10.1016/j.jtbi.2008.08.006.
  81. Helinski MEH, Hassan MM, El-Motasim WE, Malcolm CA, Knols BGJ, El-Sayed B. Towards a sterile insect technique field release of Anopheles arabiensis mosquitoes in Sudan: irradiation, transportation, and field cage experimentation. Malaria J. 2008;7:65–74
  82. Bryan CS, Moss SW, Kahn RJ. Yellow fever in the Americas. Infect Dis Clin North Am. 2004;18:275–292
  83. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA. 2008;300(8):960–962
  84. Klempner MS, Unnasch TR, Hu LT. Taking a bite out of vector-transmitted infectious diseases. N Engl J Med. 2007;356(25):2567–2569
  85. Muller P, Warr E, Stevenson BJ, Pignatelli PM, Morgan JC, Steven A, et al. Field-caught permethrin-resistant Anopheles gambiae overexpress CYP6P3, a P450 that metabolises pyrethroids. PLoS Genet. 2008;4(11):e1000286
  86. World Health Organization. The use of DDT in malaria vector control: WHO position statement. Accessed January 9, 2009 http://www.who.int/malaria/docs/IRS/DDT/DDTposition.pdf2007;
  87. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and proposing solutions for control of Aedes aegypti. PLoS Med. 2008;5(3):e68
  88. Kay B, Nam VS. New strategy against Aedes aegypti in Vietnam. Lancet. 2005;365:613–617
  89. Hayes EB, O'Leary DR. West Nile virus: a pediatric perspective. Pediatrics. 2004;113(5):1375–1381
  90. American Academy of Pediatrics. Follow safety precautions when using DEET on children. Accessed January 9, 2009 http://aapnews.aappublications.org/cgi/content/full/e200399v12003;
  91. U.S. Centers for Disease Control and Prevention. Malaria. In:  Arguin PM,  Kozarsky PE,  Reed C editor. Health information for international travel, 2008. Atlanta (GA): Centers for Disease Control and Prevention; 2007;
  92. World Health Organization. Malaria. In:  Wilder-Smith A editors. International travel and health, 2008. Geneva: World Health Organization; 2008;
  93. Borrmann S, Faucher JF, Bagaphou T, Missinou MA, Binder RK, Pabisch S, et al. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis. 2003;37:1441–1447
  94. Barrett A, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209–229
  95. World Health Organization. The Immunological Basis for Immunization Series (Module 8: Yellow Fever). Accessed January 9, 2009 http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod8_e.pdf1993;
  96. Ellis BR, Barrett AD. The enigma of yellow fever in East Africa. Rev Med Virol. 2008;18(5):331–346
  97. Gould EA, de Lamballerie X, Zanotto PM, Holmes EC. Origins, evolution, and vector/host coadaptions within the genus Flavivirus. Adv Virus Res. 2003;59:277–314
  98. Reed W, Carroll J, Agramonte A. The etiology of yellow fever: an additional note. JAMA. 1901;36(8):431–440
  99. Van der Stuyft P, Gianella A, Pirard M, Cespedes J, Lora J, Peredo C, et al. Urbanisation of yellow fever in Santa Cruz (Bolivia). Lancet. 1999;353:1558–1562
  100. U.S. Centers for Disease Control and Prevention. Outbreak notice—Yellow fever in Paraguay—updated, 13 June 2008. Accessed December 1, 2008 http://www.cdc.gov/travel/contentYellowFeverParaguay.aspx
  101. Broom AK, Smith DW, Hall RA, Johansen CA, MacKenzie JS. Arbovirus infections. In:  Cook GC,  Zumla AI editor. Manson's Tropical Diseases. 21st Edition. London, England: Elsevier; 2004;
  102. Weir E, Haider S. Yellow fever: readily prevented but difficult to treat. CMAJ. 2004;170(13):1909–1910
  103. Chao D, Davis B, Chang G. Development of multiplex real-time reverse transcriptase PCR assays for detecting eight medically important flaviviruses in mosquitoes. J Clin Microbiol. 2007;45(2):584–589
  104. Jackson GW, McNichols RJ, Fox GE, Wilson RC. Toward universal Flavivirus identification by mass cataloging. J Mol Diagn. 2008;10(2):135–141
  105. Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antivir Res. 2009;81(1):6–15
  106. World Health Organization. Yellow fever vaccine. Accessed January 9, 2009 www.who.int/vaccines/en/yellowfever.shtml
  107. Orozco J. Defeating dengue: a difficult task ahead. Bull World Health Organ. 2007;85(10):737–738
  108. Monath TP. Dengue and yellow fever—challenges for the development and use of vaccines. N Engl J Med. 2007;357:2222–2225
  109. Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Exp Rev Vacc. 2008;7(5):579–587
  110. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–6082
  111. World Health Organization. Vaccine-preventable diseases and vaccines. In:  Wilder-Smith A editors. International travel and health, 2008. Geneva: World Health Organization; 2008;
  112. Poland JD, Calisher CH, Monath TP. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895–900
  113. World Health Organization. Mali: 6 million vaccinated against yellow fever. Accessed January 9, 2009 www.who.int/features/2008/mali_vaccine/en/2008;
  114. Ministerio da Saude, Brasil. Epizootia de primates por febre amarela no Noroests do Estado do Rio Grande do Sul. Accessed January 9, 2009 http://portal.saude.gov/br/portal/arquivos/pdf/epizootia_primatas_fa_2008.pdf2008;
  115. Pan American Health Organization. Final statement by the Pan American Health Organization/World Health Organization (PAHO/WHO) on investigation of serious adverse events in Peru following receipt of yellow fever vaccine produced by Bio-Manguinhos, Brazil. Accessed January 9, 2009 http://www.paho.org/English/AD/FCH/IM/PAHO_WHOStatement_YellowFever_11Aug08.pdf2008;
  116. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?. Comp Immunol Microbiol Infect Dis. 2004;27:319–330
  117. Hung NT, Lan NT, Lei HY, Lin YS, Lien LB, Huang KJ, et al. Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg. 2006;74(4):684–691
  118. Teixeira MG, Costa MC, Coehlo G, Barreto ML. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg Infect Dis. 2008;14(10):1663
  119. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004;22:1275–1280
  120. Pan American Health Organization. Dengue in the Americas: the epidemics of 2000. Epidemiol Bull. 2000;21:4–8
  121. Pan American Health Organization. 2008: Number of reported cases of dengue and dengue hemorrhagic fever (DHF), region of the Americas. Accessed January 9, 2009 http://www.paho.org/english/ad/dpc/cd/dengue-cases-2008.htm
  122. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med. 2005;353(9):924–932
  123. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol. 2003;27:1–13
  124. Hung LT, Lan NT. Improvement of case management: a key factor to reduce case-fatality rate of dengue hemorrhagic fever in southern Vietnam. Dengue Bull. 2003;22:144–148
  125. Bandyopadhyay S, Lum LC, Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue hemorrhagic fever. Trop Med Int Health. 2006;11(8):1238–1255
  126. Guzman MG, Kouri G, Diaz M, Llop A, Vazquez S, Gonzalez D, et al. Dengue, one of the great emerging health challenges of the 21st Century. Exp Rev Vacc. 2004;3:511–520
  127. Phuong C, Nhan N, Kneen R, Thuy P, Thien C, Nga N, et al. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the World Health Organization classification scheme useful?. Am J Trop Med Hyg. 2004;70(2):172–179
  128. Balmaseda A, Hammond S, Perez M, Cuadra R, Solano S, Rocha J, et al. Short report: Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Trop Med Hyg. 2005;73(6):1059–1062
  129. Colbert JA, Gordon A, Roxelin R, Silva S, Silva J, Rocha C, et al. Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J. 2007;26:850–852
  130. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, Kalayanarooj S, et al. Natural history of plasma leakage in dengue hemorrhagic fever, a serial ultrasonographic study. Pediatr Infect Dis J. 2007;26:283–290
  131. Tantracheewathorn T, Tantracheewathorn S. Risk factors of dengue shock syndrome in children. J Med Assoc Thai. 2007;90(2):272–277
  132. Chacko B, Subramanian G. Clinical, laboratory and radiological parameters in children with dengue fever and predictive factors for dengue shock syndrome. J Trop Pediatr. 2008;54(2):137–140
  133. Restrepo B, Ramirez RE, Arboleda M, Alvarez G, Opsina M, Diaz F. Serum levels of cytokines in two ethnic groups with dengue virus infection. Am J Trop Med Hyg. 2008;79(5):673–677
  134. LaFleur C, Granados J, Vargas-Alarcon G, Ruiz-Morales J, Villareal-Garza C, Higuera L, et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol. 2002;63(11):1039–1044
  135. Soundravally R, Hoti SL. Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: role of TAP and HPA gene polymorphism. Hum Immunol. 2007;68(12):973–979
  136. Soundravally R, Hoti SL. Polymorphisms of TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand J Immunol. 2008;67(6):618–625
  137. Fink J, Gu F, Vasudevan S. Role of T cells, cytokines and antibody in dengue fever and dengue hemorrhagic fever. Rev Med Virol. 2006;16:263–275
  138. Kouri G, Guzman MG, Bravo J. Hemmorhagic dengue in Cuba: history of an epidemic. Bull Pan Am Health Organ. 1986;20:24–30
  139. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis. 2003;7(3):231–232
  140. Pelaez O, Guzman MG, Kouri G, Perez R, San Martin JL, Vazquez S, et al. Dengue 3 epidemic (Havana, 2001). Emerg Infect Dis. 2004;10(4):719–722
  141. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis. 2002;8(12):1474–1479
  142. Guzman MG, Kouri GP. Dengue: an update. Lancet Infect Dis. 2002;185:1213–1221
  143. Dussart P, Petit L, Labeau B, Bremand L, Leduc A, Moua D, et al. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Neglected Trop Dis. 2008;2(8):e280
  144. Wichmann O, Lauschke A, Frank C, Shu PY, Niedrig M, Huang JH, et al. Dengue antibody presence in German travelers. Emerg Infect Dis. 2005;11:762–765
  145. Dussart P, Labeau B, Lagathu G, Louis P, Nunes MR, Rodrigues SG, et al. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol. 2006;13:1185–1189
  146. Kumarasamy V, Wahab AH, Chua SK, Hassan Z, Chem YK, Mohamad M, et al. Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infection. J Virol Methods. 2007;140:75–79
  147. Wilde H, Suankratay C. There is a need for antigen-based rapid diagnostic tests to identify common acute tropical illnesses. J Travel Med. 2007;14(4):254–258
  148. Wills BA, Dung NM, Loan HT, Tam DT, Thuy TT, Minh LT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353:877–889
  149. Guzman MG, Kouri G, Halstead SB. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?. Lancet. 2000;355:1902–1903
  150. Ranjit S, Kissoon N, Jayakumar I. Aggressive management of dengue shock syndrome may decrease mortality rate: a suggested protocol. Pediatr Crit Care Med. 2005;6(4):412–419
  151. Soni A, Chugh K, Sachdev A, Gupta D. Management of dengue fever in ICU. Indian J Pediatr. 2001;68(11):1051–1055
  152. Futrakul P, Poshyachinda M, Mitrakul C, Kwakpetoon S, Unchumchoke P, Teranaparin C, et al. Hemodynamic response to high-dose methyl prednisolone and mannitol in severe dengue-shock patients unresponsive to fluid replacement. Southeast Asian J Trop Med Public Health. 1987;18(3):373–379
  153. Lum L, Goh A, Chan P, El-Amin A, Lam S. Risk factors for hemorrhage in severe dengue infections. J Pediatr. 2002;140:629–631
  154. Tan PC, Rajasingam G, Devi S, Omar SZ. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome. Obstet Gynecol. 2008;111:1111–1117
  155. Waduge R, Malavige GN, Pradeepan M, Wijeyaratne CN, Fernando S, Seneviratne SL. Dengue infections during pregnancy: a case series from Sri Lanka and review of the literature. J Clin Virol. 2006;37:27–33
  156. Maroun SL, Marliere RC, Barcellus RC, Barbosa CN, Ramos JR, Moreira ME. Case report: vertical dengue infection. J Pediatr (Rio J). 2008;84:556–559
  157. Pediatric Dengue Vaccine Initiative website. Accessed January 9, 2009 www.pdvi.org
  158. Hayes JM, Garcia-Rivera E, Flores-Reyna R, Suarez-Rangel G, Rodriguez-Mata T, Coto-Portillo R, et al. Risk factors for infection during a severe dengue outbreak in El Salvador in 2000. Am J Trop Med Hyg. 2003;69(6):629–633
  159. Heintze C, Velasco Garrido M, Kroeger A. What do community-based dengue control programmes achieve? (A systematic review of published evaluations). Trans Royal Soc Trop Med Hyg. 2007;101:317–325
  160. McCall PJ, Lenhart A. Dengue control. Lancet Infect Dis. 2008;8:7–8
  161. Kroeger A, Lenhart A, Ochoa M, Villegas E, Levy M, Alexander N, et al. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomized trials. BMJ. 2006;332(7552):1247–1252
  162. Lenhart A, Orelus N, Maskill R, Alexander N, Streit T, McCall PJ. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health. 2008;13(1):56–67
  163. Morens DM, Fauci DS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA. 2008;299(2):214–216
  164. Enserink M. Entomology (A mosquito goes global). Science. 2008;321(5896):864–866
  165. Reiter P, Lathrop S, Bunning M, Biggerstaff B, Singer D, Tiwari T, et al. Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis. 2003;9:86–89
  166. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354(2):119–130
  167. Solomon T. Control of Japanese encephalitis—within our grasp?. N Engl J Med. 2006;355(9):869–871
  168. Solomon T. Flavivirus encephalitis. N Engl J Med. 2004;351:370–378
  169. Ooi MH, Lewthwaite P, Lai BF, Mohan A, Clear D, Lim L, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in Central Sarawak, Malaysia, 1997-2005. Clin Infect Dis. 2008;47:458–468
  170. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TY, et al. Interferon alfa-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet. 2003;361:821–826
  171. Cardosa MJ, Wang SM, Sum MS, Tio PH. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol. 2002;2:9
  172. Lacey LA. Bacillus thuringiensis serovariety israelensis and Bacillus sphaericus for mosquito control. J Am Mosq Control Assoc. 2007;23(Suppl 2):133–163
  173. Teng HJ, Lu LC, Wu YL, Fang JG. Evaluation of various control agents against mosquito larvae in rice paddies in Taiwan. J Vector Ecol. 2005;30(1):126–132
  174. Marten GG, Reid JW. Cyclopoid copepods. J Am Mosq Control Assoc. 2007;23(Suppl 2):65–92
  175. Solomon T. New vaccines for Japanese encephalitis. Lancet Neurol. 2008;7:116–118
  176. Fischer M, Casey C, Chen R. Promise of new Japanese encephalitis vaccines. Lancet. 2007;370:1806–1808
  177. Tauber E, Kollaristch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, et al. Safety and immunogenecity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial. Lancet. 2007;370:1847–1853
  178. U.S. Centers for Disease Control and Prevention. Japanese Encephalitis Vaccination. Accessed January 9, 2009 http://www.cdc.gov/vaccines/vpd-vac/j-enceph/default.htm
  179. Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Case report: Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol. 2008;43:93–95
  180. World Health Organization. Vaccine-preventable diseases and vaccines. In:  Wilder-Smith A editors. International Travel and Health, 2008. Geneva: World Health Organization; 2008;
  181. Ostlund MR, Kan B, Karlsson M, Vene S. Japanese encephalitis in a Swedish tourist after traveling to Java and Bali. Scand J Infect Dis. 2004;6(-7):512–513
  182. Centers for Disease Control and Prevention. Japanese encephalitis in a U.S. traveler returning from Thailand, 2004. MMWR. 2005;54:123–125
  183. Jelinek T. Japanese encephalitis vaccine in travelers. Exp Rev Vacc. 2008;7(5):689–693
  184. Reimann CA, Hayes EB, Di Guiseppi C, Hoffman R, Lehman J, Lindsey NP, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg. 2008;79(6):974–979
  185. Centers for Disease Control and Prevention. West Nile virus activity—United States, 2006. MMWR. 2007;56(22):556–559
  186. Ligon BL. Reemergence of an unusual disease: the Chikungunya epidemic. Semin Pediatr Infect Dis. 2006;17:99–104
  187. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev. 2001;14(4):909–932
  188. Suhrbier A, Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol. 2004;16:374–379
  189. de Lamballerie X, Leroy E, Charrel RN, Ttsetsarkin K, Higgs S, Gould EA. Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come?. Virology J. 2008;5:33–36
  190. Vazeille M, Jeannin C, Martin E, Schaffner F, Failloux A. Chikungunya: a risk for Mediterranean countries?. Acta Tropica. 2008;105:200–202
  191. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks—the globalization of vectorborne diseases. N Engl J Med. 2007;356(8):769–771
  192. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al. Multidisciplinary prospective study of mother-to-child Chikungunya virus infections on the island of La Reunion. PLoS Med. 2008;5(3):413–423
  193. Renault P, Solet J, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of Chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg. 2007;77(4):727–731
  194. Borgherini G, Poubeau P, Joussaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associated with Chikungunya virus: a study of 88 adult patients on Reunion Island. Clin Infect Dis. 2008;47:469–475
  195. Dent AE, Kazura JW. Lymphatic filariasis (Brugia malayi, Brugia timori, Wucheria bancrofti). In:  Kliegman RM,  Behrman RE,  Jenson HB, et al. editor. Nelson Textbook of Pediatrics. 18th Edition. Philadelphia (PA): Elsevier; 2007;
  196. Simonsen PE. Filariases. In:  Cook GC,  Zumla AI editor. Manson's Tropical Diseases. 21st Edition. London, England: Elsevier; 2004;
  197. Drugs for parasitic infections. Med Lett Drugs Ther. 2007;5:e1–e15
  198. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis. 2008;21:673–681
  199. Blackburn BG, Eigege A, Gotau H, Gerlong G, Miri E, Hawley WA, et al. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. Am J Trop Med Hyg. 2006;75(4):650–655

PII: S1538-5442(09)00014-5

doi: 10.1016/j.cppeds.2009.01.001

Current Problems in Pediatric and Adolescent Health Care
Volume 39, Issue 4 , Pages 97-140 , April 2009

Article Tools

* Image Usage & Resolution